News

BioSpace1d
Regeneron Comes to 23andMe’s Rescue With $256M Acquisition Plan
DB-OTO, which Regeneron obtained from the 2023 acquisition of Decibel Therapeutics for $109 million, works by delivering a ...
Regeneron's first-quarter results miss on lower Eylea demand
Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug ...
23andMe sale grafts a happy ending on to a glum tale
Being spliced on to Regeneron will free the genetic testing company from its fatal dependence on sporadic revenue ...
REGN Q1 Earnings Call: Pipeline Progress and EYLEA Headwinds Dominate Discussion
Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...
FiercePharma21d
Regeneron's Eylea franchise suffers double whammy with sales decline and surprise FDA rejection
After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker. Over the first three months of 2025, Regeneron's ...
Morningstar21d
Regeneron's Portfolio Still Supports a Narrow Moat Despite Competitive Threats to Eylea
Moreover, in April 2025, Regeneron's US supplementary application for Eylea HD's prefilled syringe was rejected; this packaging format is important for the product's competitiveness with Vabysmo ...
Regeneron Upgraded as AbbVie Catches Policy Heat
With pricing reforms and PBM overhauls looming, pharma investors need to differentiate between companies that can absorb ...
Nasdaq22d
Regeneron Highlights New Real-World And Clinical Data On EYLEA HD At ARVO 2025
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced the presentation of 27 abstracts, including eight oral sessions, featuring EYLEA HD (aflibercept) Injection 8 mg at the upcoming ARVO ...